Intergroup collaboration in ovarian cancer: a giant step forward.
The rather slow evolution of so-called "optimal chemotherapy" for ovarian cancer is the result of suboptimal randomised clinical trials, not having the statistical power to identify truly superior regimens, and of the lack of systematic comparisons of new agents with relevant control arms. There is little doubt that we need international collaboration to move the field forward in a timely and coherent manner. European and transatlantic collaboration represents the beginning of the process and point to the success that can await us if the drive to work together remains strong. A similar organisation as for breast cancer (Breast International Group, BIG) needs to be established for ovarian cancer.
Piccart
M J
MJ
Institut Jules Bordet, Bruxelles, Belgium. mpiccart@ulb.ac.be
Stuart
G C
GC
Cassidy
J
J
Bertelsen
K
K
Parmar
M K
MK
Eisenhauer
E A
EA
Kaye
S B
SB
Tropé
C
C
Swenerton
K
K
Harper
P
P
Vermorken
J B
JB
D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007373:Interinstitutional Relations; D007391:International Cooperation; D015337:Multicenter Studies as Topic; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D015203:Reproducibility of Results; D012107:Research Design; D018401:Sample Size